Global Liposome Drug Delivery Market, By Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Others), Indication (Fungal Diseases, Cancer Therapy, Viral Vaccines, Pain Management, Others), Technology ( Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome (LTSL)), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Liposome Drug Delivery Market Analysis and Size
The global liposome drug delivery market is expected to witness significant growth during the forecast period. Liposomes enable a diverse range of drugs which contributes to the growth of the global market. Companies in the liposome drug delivery market are increasing their research in nanomaterials such as nanospheres, liposomes, and nanoparticles which are effective antiviral agents. Liposome drug delivery is being balanced with increased in vivo and in vitro drug activities for regular clinical practices. Several liposome drug delivery companies are increasing their R&D activities to reveal new lipid compositions and strategies that improve liposome's stability and drug vehiculization capabilities.
Data Bridge Market Research analyses a growth rate in the global liposome drug delivery market in the forecast period 2022-2029. The expected CAGR of global liposome drug delivery market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 4.16 billion in 2021, and it would grow upto USD 8.0 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Nano-carriers such as liposome have been recognized as widespread acceptance for diverse therapeutic applications. Liposome vesicular structures are comprised of one lipid bilayers. It can act as a carrier of drugs, which can be used to deliver drugs for treating cancer and other disorders. As a result, industry participants in the liposomal drug delivery devices market are expected to benefit from lucrative growth prospects throughout the forecast period. This is further anticipated to impede the growth of the liposomal drugs market in the timeline period.
Liposome Drug Delivery Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Others), Indication (Fungal Diseases, Cancer Therapy, Viral Vaccines, Pain Management, Others), Technology ( Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome (LTSL)), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Janssen Pharmaceuticals, Inc. (Belgium), CELSION corporation (U.S.)., Abbott (U.S.), Ipsen Pharma (France), Spectrum Pharmaceuticals, Inc. (U.S.), Takeda Pharmaceutical Company Limited. (Japan)
|
|
Market Opportunities
|
|
Global Liposome Drug Delivery Market Dynamics
Drivers
- Greater Adoption of Quality by Design (QbD) Over Traditional Processes
Processes have been modernized as a result of the adoption of rational-based approaches such as QbD over empirical and simulation-based approaches. Compared to conventional methodologies that are focused on trial and error, QbD is based on a fact-based rational approach and aids in more robust decision-making. The popularity and implementation of the QbD technique are anticipated to rise.
- Increased Strategies
Several new strategies in surface modification of liposomes are generating incremental opportunities for pharmaceutical companies. The liposome drug delivery is being highly applicable as a useful biocompatible tool for the vehiculation and delivery of lipophilic, hydrophilic, and amphiphilic compounds. Thus, it boosts the market growth.
Opportunities
- Enhancing Circulation Time of Hydrophobic Substances
Galbanic acid (Gba) in improved liposomal formulations are used in the liposome drug delivery market to make the most of the therapeutic efficacy of PEGylated liposomal Doxorubicin. Galbanic acid has a favourable future as an anti-cancer drug. Galbanic acid's water solubility restrictions, however, restrict its potential for use in medicine. To eradiciate the drawbacks of poor Gba solubility, businesses in the liposome drug delivery market are increasing the application of PEGylated liposomal Gba made using the thin film hydration plus extrusion approach.
- Side Effects
There are various side effects that are associated with liposome drugs such as facial swelling, cough, pain, numbness, blistering and many others. This acts as a hindrance to the market.
Restraints/Challenges
- High Cost
The huge expenditure required for developing the liposomal drugs hamper the market growth.
- Side Effects
There are various side effects that are associated with liposome drugs such as facial swelling, cough, pain, numbness, blistering and many others. This acts as a hindrance to the market.
This global liposome drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global liposome drug delivery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Liposome Drug Delivery Market Scope
The global liposome drug delivery market is segmented on the basis of product, indication, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Technology
- Stealth Liposome Technology
- Non-PEGylated Liposome Technology
- DepoFoam Liposome Technology
- Lysolipid Thermally Sensitive Liposome (LTSL)
Product
- Liposomal Doxorubicin
- Liposomal Paclitaxel
- Liposomal Amphotericin B
- Others
Indication
- Fungal Diseases
- Cancer Therapy
- Viral Vaccines
- Pain Management
- Others
End-user
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Liposome Drug Delivery Market Regional Analysis/Insights
The global liposome drug delivery market is analysed and market size insights and trends are provided by product, indication, end-user and distribution channel as referenced above.
The major countries covered in the global liposome drug delivery market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global liposome drug delivery market due to the increase prevalence of cancer and advanced healthcare facilities.
Asia-Pacific is expected to witness huge growth in the liposomal drugs market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Liposome Drug Delivery Market Share Analysis
The global liposome drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global liposome drug delivery market
Key players operating in the global liposome drug delivery market include:
- Johnson & Johnson Services, Inc. (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Janssen Pharmaceuticals, Inc. (Belgium)
- CELSION corporation (U.S.)
- Abbott (U.S.)
- Ipsen Pharma (France)
- Spectrum Pharmaceuticals, Inc. (U.S.)
- Takeda Pharmaceutical Company Limited. (Japan)
SKU-